New target for retinopathy therapy discovered

Article

A variant form of vascular endothelial growth factor (VEGF) has been discovered to be responsible for the inflammation and altered retinal vascularization that occurs in conditions such as diabetic retinopathy.

A variant form of vascular endothelial growth factor (VEGF) has been discovered to be responsible for the inflammation and altered retinal vascularization that occurs in conditions such as diabetic retinopathy (DR), according to an announcement made at the European meeting on Vascular Biology and Medicine in Bristol, England.

Professor David Shima from University College London, UK and co-workers discovered that, although blood vessels in the ischaemic retina re-grow, they do so in a disorganized fashion, forming clumps rather than a fine, mesh-like network. The researchers characterized the VEGF activity responsible for the abnormal response and identified an isoform, VEGF 164, which drives ocular neovascularization, vascular permeability and an inflammatory reaction.

When VEGF 164 was inhibited, either genetically or pharmaceutically, pathological neovascularization was also inhibited and blood vessels were able to form normally. Further investigation found a specific region within VEGF 164 that is a major cause of DR inflammation.

Although this inflammatory function of VEGF 164 represents a target for DR treatment, VEGF has a second, beneficial role in protecting neurons from ischaemic death, so eliminating it completely could trigger unwanted consequences.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
© 2025 MJH Life Sciences

All rights reserved.